OraSure Technologies Continues its Dedication to Ending the HIV Epidemic – Yahoo Finance
Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day
BETHLEHEM, Pa., Dec. 01, 2022 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in the fight against HIV, will ring the closing bell for the Nasdaq Stock Market this afternoon in honor of World AIDS Day. World AIDS Day is commemorated annually on December 1 to raise awareness of the AIDS epidemic and to mourn the loss of those who have died of the disease. The U.S. Government’s theme for this year’s World AIDS Day is “Putting Ourselves to the Test: Achieving Equity to End HIV,” to emphasize the importance of uplifting marginalized and vulnerable groups who bear the brunt of the burden of HIV in the country.
“OraSure has played a critical role in the fight against HIV globally since 2002. For more than two decades, we have championed the importance of access to personal information about health through easy-to-use diagnostics, particularly for vulnerable communities around the world most burdened by HIV,” said OraSure President and CEO Carrie Eglinton Manner. “Today we vow to continue that fight, both globally through partnership with non-governmental organizations that provide tests to low- and middle-income countries to help combat the HIV crisis, and domestically through innovative programs like the Centers for Disease Control and Preventions (CDC) ‘Take Me Home,’ HIV self-test program.”
Under the CDC program, OraSure may supply up to one million OraQuick® In-Home HIV tests to engage individuals who are disproportionately affected by HIV and less likely to have access to key diagnostic, prevention, and treatment services across the United States.
Almost 1.2 million people aged 13 and older have HIV in the United States, including an estimate of nearly 160,000, who currently do not know that they are infected. Identifying these individuals and linking them to care is a crucial priority for eradicating HIV. With pre-exposure prophylaxis (PrEP), a medication used by HIV-negative individuals to prevent HIV seroconversion, people can take control of their health and prevent infection before it starts. For people living with HIV, effective treatment allows them to enjoy long and healthy lives and, with an undetectable viral load, means that they cannot transmit HIV through sex. This is commonly known as U=U, or “undetectable equals untransmittable.”
OraSure was the first company to receive FDA approval for a professional-use rapid HIV-1 test in 2002 with its OraQuick® Rapid HIV-1 Antibody Test. In 2012, the Company received FDA approval for the first, and still only, over-the-counter oral fluid HIV test, the OraQuick® In-Home HIV Test. In 2017, the Company received World Health Organization (WHO) prequalification for the OraQuick® HIV Self-Test, which is sold for use by individuals internationally, including significant use in sub-Saharan Africa which has the highest rates of HIV globally. More than 90 million OraQuick® HIV tests have been used worldwide in more than 130 countries, helping link those who test positive to appropriate confirmation testing and care. The Company is also developing new diagnostic tests to support clinicians in improving adherence to PrEP, ensuring that the medication is used consistently so that high-risk individuals without HIV remain free of infection.
In addition to the Nasdaq closing bell ceremony, OraSure employees will also meet with key opinion leaders and those who help represent and serve marginalized communities most burdened by HIV and will support awareness, testing and treatment initiatives around the globe.
About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
About OraSure Technologies’ HIV Tests
The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test is the first FDA approved, CLIA-waived, rapid point-of care test that can detect antibodies to both HIV-1 and HIV-2 with greater than 99 percent accuracy in as little as 20 minutes, using an oral fluid, finger-stick or venipuncture whole blood, or plasma sample. The OraQuick® In-Home HIV Test is the first and only oral fluid rapid over-the-counter (OTC) HIV test approved in the U.S. The OraQuick® In-Home HIV Test can detect antibodies to both HIV-1 and HIV-2 with an oral swab, providing a confidential in-home testing option with results in as little as 20 minutes. It is the first rapid diagnostic test for any infectious disease that has been approved by the FDA for sale to the consumer market. The OraQuick® HIV Self-Test (HIVST) is a rapid, point-of-care test that allows an individual to detect antibodies to both HIV-1 and HIV-2 with a simple oral swab and provides a result in as little as 20 minutes in the privacy of an individual’s home, at outreach testing settings, in the pharmacy or at community-based screening events. Based on the same OraQuick® platform that is used for the FDA-approved OraQuick® In-Home HIV Test and the WHO Prequalified OraQuick® Rapid HIV-1/2 Antibody Test used by health care professionals worldwide, the platform has been used to test millions in international markets.
Important Information
This press release contains certain forward-looking statements, including with respect to the Company’s products, product development activities, regulatory submissions and authorizations and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: risk that the Company’s exploration of strategic alternatives may not result in any definitive transaction or enhance stockholder value and may create a distraction or uncertainty that may adversely affect operating results, business or investor perceptions; the diversion of management’s attention from the Company’s ongoing business and regular business responsibilities due to the Company’s exploration of strategic alternatives; ability to resolve the Company’s ongoing manufacturing challenges and satisfy customer demand; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on the Company’s business and ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
Investor Contact:
Scott Gleason
SVP Investor Relations & Corporate Communications Communications
484-425-0588
sgleason@orasure.com
Media Contact:
Amy Koch
Sr. Mgr. Corporate Communications
484-523-1815
media@orasure.com
Related Quotes
Bill Gates looks for income, too. This is how he gets it.
Tesla, the electric vehicle industry's top manufacturer, has delivered good news to its investors, customers and fans lately as it rolled out its first EV semi trucks on Dec. 1. Ford , the No. 2 EV company in the U.S. after Tesla , also had great news for its investors and customers as it reported a 103% increase in EV sales year-over-year in November. Data provided by S&P Global Mobility on Nov. 29 placed Tesla at the top of the EV market with a 65% share with Ford registering about 7% of the market.
New year, new Social Security rules.
At least eight universities have partnered with online sports betting companies, reports The New York Times.
Few embody this mindset better than Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) chairman and chief executive officer, Warren Buffett. RH (NYSE: RH), formerly known as Restoration Hardware, is one of the more interesting investments by Buffett's holding company, which owns a 9.9% stake that's worth $661 million.
This money management maven doesn't mince words when it comes to financial faux-pas.
The Opec cartel has warned it could take immediate action on adjusting oil output as the group of producing nations braces for the fallout of fresh Western sanctions on Russia.
Warren Buffett is well-known for saying that his preferred holding period for stocks is "forever," and it's not too surprising why. Innovative Industrial Properties (NYSE: IIPR) is a stock I'll never sell because I expect it to keep paying me money for holding it indefinitely. In case you aren't familiar, IIP is a real estate investment trust (REIT) that buys and rents out cultivation floorspace to cannabis companies.
SBF, as Bankman-Fried was often called, says he didn’t commit fraud. But bankruptcy specialists say the findings so far are ‘pretty devastating.’
These low-beta stocks offer a diversifying effect on one's portfolio, in that they tend to move separate from the broader market.
Building a million-dollar retirement nest egg might seem daunting. For example, putting $300 a month into an investment that returns 12% annually would grow into $1 million in about 30 years. While that's slightly above the stock market's average annual return of about 9.9% over the last three decades, many companies have delivered that level of return.
Will Healy (MercadoLibre): MercadoLibre could prosper in 2023 on its antifragility. One example of MercadoLibre's antifragility is how it makes e-commerce possible in its region. To succeed, MercadoLibre has to reach customers who do not hold bank accounts or credit cards.
Cloud computing is a massive industry right now and still growing, with an estimated market size of $1.5 trillion by 2030, according to Grand View Research. Lots of tech companies have their hands in cloud computing these days, so where should investors even begin? Two great places to start are with The Trade Desk (NASDAQ: TTD) and Amazon (NASDAQ: AMZN).
FTX’s founder said he couldn’t explain what happened to billions of dollars that customers of his failed cryptocurrency exchange sent to the bank accounts of his trading firm.
Even the world’s richest man can’t have everything.
The market is down on these stocks despite the fact that they continue to grow through a challenging environment.
(Bloomberg) — OPEC+ responded to surging volatility and growing market uncertainty by keeping its oil production unchanged. Most Read from BloombergOPEC+ Latest: Group Agrees to Keep Oil Production UnchangedElon Musk Says Apple Is ‘Fully’ Advertising on Twitter AgainThis Stock Strategist Says We’ll See 5% Inflation for the Next DecadeTrophy Rolex, Patek and Audemars Piguet Prices Skid to Pre-Boom LevelsMusk Hails Release of Twitter Emails on Hunter Biden StoryThe outcome of the brief online mee
We looked at the performance of all sorts of fixed-income securities over the past 50 years. Here’s what we found.
Salesforce (NYSE: CRM) posted its latest quarterly report on Nov. 30. Its adjusted earnings increased 10% to $1.40 per share and also cleared the consensus forecast by $0.18. Salesforce's growth rates seemed stable, but they didn't impress the bulls.
Saving for retirement is a lifelong undertaking. It involves keeping your retirement goals in mind as you have children, get different jobs and move from place to place. However, a recent study from the Center for Retirement Research at Boston College … Continue reading → The post Empty Nester? This Avoidable Mistake Could Jeopardize Your Retirement appeared first on SmartAsset Blog.